Funding for this research was provided by:
Institut National de la Santé et de la Recherche Médicale
Conseil Régional, Île-de-France (PhD)
Received: 19 April 2019
Accepted: 25 June 2019
First Online: 12 July 2019
Ethics approval and consent to participate
: Ethics approval and consent to participate: all patients gave their informed consent for metabolic investigations at baseline and after 1 year of therapy, and for self-questionnaire used which were approved by the local ethics committee (Comité de Protection des Personnes, Paris-St-Louis).
: All authors reviewed and approved the final article.
: C Va has received personal fees for consultancy, travel, or accommodation from Aegerion Pharmaceuticals, Lilly, Novo Nordisk, Sanofi, Servier, and Vitalaire. MCV was invited by Aegerion for a conference (transportation and accommodation, with no other fee) as received non-financial support from Novartis and Ipsen and personal fees for lecture, travel, or accommodation by Sanofi and GSK. C Vi has received personal fees for consultancy, lecture, travel, or accommodation from Aegerion Pharmaceuticals, Air Products, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Jansen-Cilag, Merck-Serono, Novo Nordisk, Orkyn, Sanofi, Servier, Viiv-Healthcare, and Vitalaire, and institutional research grants from Pierre-Fabre Médicament, Roche Diagnostics and Servier. JFG has received personal fees for consultancy, lecture, travel, or accommodation from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novartis, Novo Nordisk, Sanofi-Aventis and Servier. He has received research grants from Eli Lilly, Novo Nordisk and Sanofi. DK, AD, OL, IJ, MB have nothing to declare.